Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Jochen Salfeld, PhD

Targets & Therapeutics: Lessons Learned from Humira and other TNF Antagonists

AbbVie Bioresearch Center

Tomoyuki Igawa, Ph.D.

Drug Discovery Driven by Antibody Engineering Technologies

Chugai Pharmabody Research Pte. Ltd., Singapore

Junichi Koga, PhD

ADCs, Bispecifics, Cell Therapies and Oncolytic Virus Therapies: Daiichi Sankyo’s Innovative Therapeutic Development Progress and Pipeline

Daiichi Sankyo

Kouhei Tsumoto, PhD

How We Can Improve the Affinity of An Antibody

The University of Tokyo

Feb 26
Show Filter
08:00 - 09:00 60 mins
Registration and Coffee
09:00 - 09:15 15 mins
Pre-Conference Workshop
Workshop Moderators' Opening Remarks
  • Sai Reddy, PhD - Assistant Professor, Department of Biosystems Science & Engineering, ETH Zurich
  • David Johnson, PhD, MBA - Founder and CEO, GigaGen, Inc.
09:15 - 09:45 30 mins
Info
Pre-Conference Workshop
Genomics and Yeast Display for Antibody Discovery and Engineering
  • David Johnson, PhD, MBA - Founder and CEO, GigaGen, Inc.

In this session, we will discuss how display, deep sequencing, and bioinformatics can be integrated into antibody discovery and engineering programs. On the discovery side, such methods can be used to fine tune mouse immunization protocols and rapidly identify antibodies with functional characteristics of interest. On the engineering side, genomics can be used to identify mutational hotspots in antibody repertoires, and facilitate affinity maturation. The sheer volume of data generated by such approaches requires fast and accurate algorithms for error correction and clustering, as well as new data management and visualization systems.

09:45 - 10:15 30 mins
Info
Pre-Conference Workshop
Antibody Design and Engineering through Integration of Computational and Experimental Methods
  • Karthik Viswanathan, Ph.D. - Director, Research, Visterra, Inc.

Over the last decade there have been significant advances in computational protein design methods, high throughput protein characterization, and availability of antibody repertoire data. Convergence of these methods enable structure-guided design and engineering of antibodies. Here we discuss, through examples, application of computational and experimental methods for lead antibody discovery.

10:15 - 10:45 30 mins
Info
Pre-Conference Workshop
Rational Selection of Antibody Clones
  • Hiroki Shirai, PhD - Executive Fellow, Modaility Research Laboratories Astellas Pharma

In silico sequence analysis is useful for the rational selection of developable, manufacturable, and “designable” clones. By using our high-resolution antibody modeling protocol which proved competitive at antibody modeling assessment II, we have recently found that one can identify the clones which are relatively easy for successful optimization. Molecular simulation and informatics approaches revealed such “design-ability” corresponds to structural versatility of CDR-H3.

10:45 - 11:15 30 mins
Pre-Conference Workshop
Networking Refreshment Break
11:15 - 11:45 30 mins
Info
Pre-Conference Workshop
Rapid Functional Interrogation of the Immune repertoire - Next Generation Antibody Discovery
  • Gabriel Cheung, PhD - Senior Director, BioMedicine Design, Pfizer

Numerous disruptive technologies, from NGS of BCRs to bottom-up serum Ig proteomic, have been developed to study B cell repertoires in the past decade. At Pfizer, we are further pushing the boundary of technologies to enable fast and comprehensive interrogation of functionally relevant, antigen specific B cells from both peripheral and bone marrow compartments through the use of proprietary high-throughput automation, novel single cell technology and deep sequencing.

11:45 - 12:15 30 mins
Info
Pre-Conference Workshop
Immune-Profiling of Human B cell Repertoire Using Next Generation Sequencing Technology
  • Junho Chung, M.D., Ph.D. - Professor, Seoul National University College of Medicine

Next-generation sequencing (NGS) has allowed a massive increase in capacity to

sequence genomes at relatively low cost and in a short time frame. It has revolutionized

multiple aspects of biological research and is actively being adopted into profiling

human B cell receptor (BCR) repertoires. Several NGS platforms are currently available,

with average read lengths of 75 bp to 8,500 bp and different error rates. Using NGS, we

successfully constructed database of BCR repertoire from human volunteers. Afterwards,

we developed algorithms for analyzing the diversity, enrichment pattern, accumulation

of somatic hyper-mutation in BCR repertoire. Through in silico analysis with machine

learning technology we devised strategies to select clones of interest. Now we are actively

applying this technology for the analysis of BCR repertoire in cancer patients.

12:15 - 12:45 30 mins
Info
Pre-Conference Workshop
Bispecific Target Discovery by High Throughput Functional Screening
  • Pallavi Bhatta, PhD - Principal Scientist, Functional Screening, UCB

To exploit the true potential to access novel biology with bispecific antibodies, we have developed technology to facilitate unbiased target pair identification and validation through grid screening large numbers of bispecific antibodies in functional human cell assays. Combination of our antibody discovery capabilities, a novel bispecific screening format and high throughput flow cytometry or imaging enables us to screen thousands of bispecific antibodies to hundreds of antigen combinations and identify new target pairs for a defined patient phenotype. The technology and a specific example application from patient phenotyping to new target pair discovery will be described.

12:45 - 12:55 10 mins
Pre-Conference Workshop
Close of Workshop
13:55 - 14:00 5 mins
Main Conference
Chairperson's Remarks
14:00 - 14:45 45 mins
Info
Main Conference
Targets & Therapeutics: Lessons Learned from Humira and other TNF Antagonists
  • Jochen Salfeld, PhD - Vice President, Global Biologics, AbbVie Bioresearch Center

The presentation will focus on the role of the underlying target biology for developing novel Biologics therapeutics using TNF and TNF antagonists as case study. I will discuss the evolution of Anti-TNF approaches, the history of adalimumab and will start to answer the question how to explain some of the apparent clinical differences between the Anti-TNF agents in clinical use today. In this context the learnings about TNF biology and the mechanism of action of TNF antagonists will be discussed and how those learnings impact the development of novel therapeutics.

14:45 - 15:30 45 mins
Info
Main Conference
Drug Discovery Driven by Antibody Engineering Technologies
  • Tomoyuki Igawa, Ph.D. - CEO and Research Head, Chugai Pharmabody Research Pte. Ltd., Singapore

Previously, antibody engineering was mainly applied to improve the properties of a parent antibody by methods such as humanization, affinity maturation, stability engineering and half-life extension. Recent advances in antibody engineering have enabled us to conceive and realize novel antibody drug concepts. This presentation describes how antibody engineering technologies can drive the discovery of innovative antibody drugs.

15:30 - 16:00 30 mins
Networking Refreshment Break
16:00 - 16:30 30 mins
Main Conference
ADCs, Bispecifics, Cell Therapies and Oncolytic Virus Therapies: Daiichi Sankyo’s Innovative Therapeutic Development Progress and Pipeline
  • Junichi Koga, PhD - Head of R&D Division, Executive Officer, Daiichi Sankyo
16:30 - 17:00 30 mins
Info
Main Conference
How We Can Improve the Affinity of An Antibody
  • Kouhei Tsumoto, PhD - Professor and Director, The University of Tokyo


Physicochemical approaches deepen our insights into antigen-antibody interactions. Recently, we have investigated how we can rationally improve the affinity of antibodies for the targets. Here I introduce our recent progress on engineering affinity of antibody based on physical biochemical approaches.

18:00 - 19:00 60 mins
Info
Networking Dinner in Tokyo

Network with fellow Antibody Engineering & Therapeutics Asia attendees from around the world by attending this Networking Dinner event at S Tokyo restaurant. Sign up to attend this optional dinner by selecting this dinner option during registration (additional fee required)

08:00 - 09:00

Registration and Coffee

More
Showing of Streams
Showing of Streams
15:30 - 16:00

Networking Refreshment Break

More
Showing of Streams
18:00 - 19:00
Info

Networking Dinner in Tokyo

Network with fellow Antibody Engineering & Therapeutics Asia attendees from around the world by attending this Networking Dinner event at S Tokyo restaurant. Sign up to attend this optional dinner by selecting this dinner option during registration (additional fee required)

More